Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neopharm Glioblastoma Drug Will Require Another Phase III Study, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Decision by agency to require another trial of cintredekin besudotox comes after the pivotal Phase III PRECISE study failed to meet its primary endpoint.

You may also be interested in...



Genentech Reports Positive Progression-Free Survival Results For Avastin In Brain Cancer Trial

Interim results of a Phase II study showed that 51 percent of patients receiving Avastin plus chemotherapy experienced six months of PFS, and 36 percent of patients taking Avastin alone had six-month PFS.

Genentech Reports Positive Progression-Free Survival Results For Avastin In Brain Cancer Trial

Interim results of a Phase II study showed that 51 percent of patients receiving Avastin plus chemotherapy experienced six months of PFS, and 36 percent of patients taking Avastin alone had six-month PFS.

NeoPharm Suspends Glioblastoma Trials Following Disappointing Phase III Results

Firm seeks meeting with FDA to determine path forward.

Related Content

Topics

UsernamePublicRestriction

Register

PS065836

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel